Tag Archives: Anika Therapeutics

June, 2018

20 June
Anika’s Drug Combo Fails to Meet Primary Endpoint in Phase 3 Trial in Knee Osteoarthritis

BEDFORD, Mass.–(BUSINESS WIRE)–Jun. 19, 2018– Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (HA) technology platform, today announced results from its CINGAL® 16-02 clinical trial, an active-comparator Phase III study being conducted to support U.S. registration. CINGAL has previously been evaluated …
Share

28 March
Anika Therapeutics’ Cingal Wins CE Mark Approval for Pain Associated with Osteoarthritis of the Knee

BEDFORD, Mass.–(BUSINESS WIRE)–Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid “HA” technology, today announced that it received CE Mark approval for CINGAL® as a medical device to treat pain associated with osteoarthritis of the knee. CINGAL is the …
Share